Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Growth Factor Signalling and Ubiquitination

Interested in DPhil or postdoctoral fellowship applications? Contact alex.bullock@cmd.ox.ac.uk

We aim to understand the molecular structure and function of protein kinases and E3 ubiquitin ligases that control cell growth and differentiation and how these might be targeted by small molecule inhibitors to address diseases such as cancer and inflammation.

The Growth Factor Signalling and Ubiquitination group is interested in the signalling pathways that control cell growth and differentiation and how these might be targeted by small molecule inhibitors to address devastating diseases such as cancer and inflammation. Our work is particularly focussed on the cross talk that regulates protein phosphorylation and ubiquitylation. We aim to understand the molecular structure and function of protein kinases and E3 ubiquitin ligases and to characterize their binding to substrates, regulatory partners and chemical inhibitors. This work involves a multidisciplinary approach using structural, chemical and cell biology as well as many collaborative studies with colleagues across industry and academia.

A major interest has been the BMP/TGF-beta family receptor serine/threonine kinase ACVR1/ALK2 which recruits and phosphorylates SMAD1/5/8 transcription factors for the control of embryogenesis, stem cell differentiation and iron metabolism. Mutations in this receptor drive the childhood brain tumour diffuse intrinsic pontine glioma, as well as the musculoskeletal disorder fibrodysplasia ossificans progressiva (FOP). We have solved the crystal structure of ALK2 to define the effects of mutation and have identified a number of small molecule inhibitors that block the aberrant ALK2 signalling found in disease models. We are currently conducting a phase 2 clinical trial of the ALK2 inhibitor saracatinib for FOP patients in collaboration with clinicians in the UK, The Netherlands and Germany.

Phosphorylation can also form a control switch for protein substrates to be recruited to E3 ubiquitin ligases for degradation. We aim to define the substrate recognition motifs that enable E3 recruitment and to determine the 3D structures of E3 ligases to characterize their binding to substrates, regulatory partners and chemical inhibitors. We have focused especially on multi-subunit Cullin-RING E3 ligase complexes and have determined how BTB-Kelch E3 ligases assemble into Cullin3 complexes through their 3-box motif and how different substrate recognition domains assemble with the SOCS box motif to form Cullin5-dependent E3 ligases. E3 ligases are also attractive targets for the design of small molecule PROTACs, which are bivalent chemical binders that recruit neo-substrates to an E3 ligase for targeted protein degradation. This approach has potential advantages over traditional occupancy-based inhibitors with respect to dosing, side effects, drug resistance and modulating 'undruggable' targets. We aim to develop small molecule binders for novel E3 ligases to expand the repertoire of E3s suitable for PROTAC development to maximise the potential of this technology.

Our team

Browser groups

Selected publications